Ava announced that it raised USD 9.7 million in a strategic Series A financing round led by the European venture capital firm Polytech Ventures. New investors such as Blue Ocean Ventures and the media company Global Sources, along with existing seed investors like Swisscom and the Zürcher Kantonalbank, contributed to the financing round.
The medical device company launched its first product in Summer 2016, a fertility tracking sensor bracelet that detects the fertile window in a woman’s cycle. Worn at night, the bracelet works by recording nine physiological factors that correspond to a rise in hormones indicating the onset of ovulation, including pulse, sleep quality and heart frequency. In the morning, the bracelet synchronises the data with Ava’s app to reveal a woman’s fertile days.
Ava was founded in Zurich in 2014. The company also has an office in San Francisco.